

THERMO FISHER SCIENTIFIC INC.

Form 8-K

May 16, 2016

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of**

**the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): May 13, 2016**

**THERMO FISHER SCIENTIFIC INC.**

**(Exact name of Registrant as specified in its Charter)**

**Delaware**  
**(State or other jurisdiction**  
**of incorporation or organization)**

**81 Wyman Street**

**1-8002**  
**(Commission**  
**File Number)**

**04-2209186**  
**(I.R.S. Employer**  
**Identification Number)**

**02451**

**Waltham, Massachusetts**  
**(Address of principal executive offices)**  
**(781) 622-1000**

**(Zip Code)**

**(Registrant's telephone number including area code)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events**

On May 13, 2016, Life Technologies Corporation (the Company), a wholly-owned subsidiary of Thermo Fisher Scientific Inc. (Thermo Fisher) entered into a settlement agreement (the Settlement Agreement) with Enzo Life Sciences, Inc. (Enzo) with respect to an action brought by Enzo against the Company on January 30, 2012, in the United States District Court for the District of Delaware, alleging patent infringement by the Company's TaqMan® probes and assays, Dynabead® oligo-dT beads, NCode oligonucleotide array products, Ion Torrent beads and chips and SOLiD beads and chips. Pursuant to the Settlement Agreement, the Company agreed to pay Enzo \$35 million (the Settlement Amount) and Enzo released the Company from past damages and granted the Company a license to the asserted patent families on products sold by the Company and its affiliates. The case will be dismissed after the Company pays the Settlement Amount. The Settlement Amount was fully reserved in Thermo Fisher's consolidated financial statements at April 2, 2016.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized, on this 16th day of May, 2016.

THERMO FISHER SCIENTIFIC INC.

By: /s/ Seth H. Hoogasian  
Seth H. Hoogasian

Senior Vice President, General Counsel  
and Secretary